Neurodegenerative Diseases and NEU3: A Promising Protein for Treatment

Target Name: NEU3

NCBI ID: G10825

NEU3

Neurodegenerative Diseases and NEU3: A Promising Protein for Treatment

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are some of the most common and debilitating conditions affecting human beings. These conditions are characterized by the progressive loss of brain cells and the formation of aggregates of neurotransmitters, including tau, beta-amyloid, and neurofilament tangles. One of the most promising strategies to treat these diseases is to target the neurotransmitters that are involved in the development and progression of these conditions. In this article, we will discuss NEU3, a protein that has been identified as a potential drug target and biomarker for neurodegenerative diseases.

NEU3 is a protein that is expressed in the brain and is involved in the breaking down of acetyl groups on neurotransmitters. The neurotransmitters are essential for the function of the brain and play a crucial role in communication between different parts of the brain. However, as the brain ages, the structure and function of these neurotransmitters can be altered, leading to the development and progression of neurodegenerative diseases.

One of the most promising ways to target neurotransmitters is to target the enzymes that break down neurotransmitters. This is because these enzymes are critical for the production and degradation of neurotransmitters, and by inhibiting these enzymes, can reduce the production of neurotransmitters and potentially slow down or reverse the progression of neurodegenerative diseases.

NEU3 is a protein that can be targeted as a drug or biomarker because of its unique structure and function. It is a single-chain protein that contains 256 amino acids and has a calculated molecular mass of 31 kDa. NEU3 is expressed in the brain and is involved in the breaking down of acetyl groups on neurotransmitters, which is critical for the production and degradation of neurotransmitters.

In addition, NEU3 is a good candidate for a biomarker because of its expression level in the brain and its ability to cross the blood-brain barrier. This means that it can be used as a marker for the diagnosis and monitoring of neurodegenerative diseases.

Furthermore, NEU3 can also be used as a drug target because of its unique structure and function. The acetylation of neurotransmitters is a critical step in their production and degradation, and inhibiting this process can be an effective way to treat neurodegenerative diseases.

NEU3 has been shown to be involved in the production and degradation of various neurotransmitters, including dopamine, serotonin, and norepinephrine. It has also been shown to interact with other proteins involved in neurotransmission, such as dopamine receptor, GABA receptor, and voltage-gated ion channels.

In addition, NEU3 has been shown to play a role in the regulation of cellular processes that are important for the survival and survival of neurons, such as cell survival, proliferation, and migration.

NEU3 is also a good candidate for a biomarker because of its expression level in the brain and its ability to cross the blood-brain barrier. This means that it can be used as a marker for the diagnosis and monitoring of neurodegenerative diseases.

In conclusion, NEU3 is a protein that has been identified as a potential drug target and biomarker for neurodegenerative diseases. Its unique structure and function make it an attractive target for the development of new treatments for these diseases. Further research is needed to fully understand the role of NEU3 in neurodegenerative diseases and to develop new treatments based on this protein.

Protein Name: Neuraminidase 3

Functions: Exo-alpha-sialidase that catalyzes the hydrolytic cleavage of the terminal sialic acid (N-acetylneuraminic acid, Neu5Ac) of a glycan moiety in the catabolism of glycolipids, glycoproteins and oligosacharides. Displays high catalytic efficiency for gangliosides including alpha-(2->3)-sialylated GD1a and GM3 and alpha-(2->8)-sialylated GD3 (PubMed:11298736, PubMed:15847605, PubMed:10861246, PubMed:20511247, PubMed:28646141, PubMed:10405317, PubMed:12011038). Plays a role in the regulation of transmembrane signaling through the modulation of ganglioside content of the lipid bilayer and by direct interaction with signaling receptors, such as EGFR (PubMed:17334392, PubMed:25922362). Desialylates EGFR and activates downstream signaling in proliferating cells (PubMed:25922362). Contributes to clathrin-mediated endocytosis by regulating sorting of endocytosed receptors to early and recycling endosomes (PubMed:26251452)

The "NEU3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NEU3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets